Oncology
Advanced and comprehensive cancer testing to support diagnosis, prognosis and guide personalized treatment.
Our Oncology testing services support precision cancer care through advanced molecular and genetic profiling. These tests provide insights into tumor biology, hereditary cancer risk, treatment response, and prognosis. Covering solid tumors, hematologic malignancies, and hereditary syndromes, our oncology panels include DNA, RNA, methylation, immunohistochemistry (IHC), and HRD analysis. Designed to aid oncologists, pathologists, and clinical teams, these tools help guide targeted therapies, immunotherapies, and personalized cancer management.
OncoStrands® Essential Combined (DNA + Fusion) / Essential DNA / Essential Fusion
Utilizes Next Generation Sequencing (NGS) to identify somatic mutations within 50 targeted genes associated with different tumour types, including lung, colon, skin, urinary bladder, stomach, thyroid and others. This assay simultaneously screens for different types of mutations including DNA hotspots from 45 genes, copy number variations (CNVs) from 14 genes and fusions from 18 genes. NOTE: Essential DNA or Essential Fusion can be ordered individually
OncoStrands® DNA 68
A 68-genes hybrid capture NGS panel with coverage of full coding regions of 68 key cancer-related genes (plus TERT promoter region), including BRCA1/2. NOTE: Can be ordered in combination with 18 genes Essential Fusion if screening for fusions is clinically important
OncoStrands® Extended
109-genes hybrid capture DNA NGS panel with coverage of full coding regions of 103 genes, including BRCA1 & BRCA2 and many other DNA damage repair genes (plus TERT promoter region). The assay also provides an accurate microsatellite instability (MSI) score (close to 170 loci). Useful for tumours in the prostate, breast, ovary & fallopian tube, pancreas, biliary tract, uterus and colon. NOTE: Can be ordered in combination with 18 genes Essential Fusion if screening for fusions is clinically important.
OncoStrands® Comprehensive
Based on TSO 500 chemistry, the assay offers a comprehensive genomic analysis of 523 genes and targets single nucleotide variations (SNVs), CNVs, fusions, splice variants, MSI and tumour mutation burden (TMB). The assay provides coverage of NCCN biomarkers testing guidelines, genes associated with FDA-approved targeted therapies and clinical trials matching for a variety of tumours. NOTE: Can be ordered with Homologous recombination deficiency (HRD) for early to late-line PARPi treatment decisions for patients with ovarian cancer.
OncoStrands® Comprehensive Fusion
Comprehensive RNA fusion genomic analysis that covers hundreds of cancer-relevant fusion-associated genes, including novel fusions. Useful for rare, undifferentiated cancers, particularly for sarcomas.
OncoStrands® HRD
HRD is reported in genomic instability score (GIS) and tBRCA1/2 status, based on Myriad Genetics proprietary algorithm and is available for Ovarian Cancer ONLY.
OncoStrands® Immunochemistry (IHC)
Supplementary to OncoStrands® Panels; optional add-on for the detection of PD-L1: PD-L1 protein on FFPE ALK: ALK protein on FFPE ROS1: ROS1 protein on FFPE MMR: Mismatch proteins (MLH1, PMS2, MSH2, MSH6) on FFPE
OncoStrands® Promoter Methylation
PCR-based methylation tests are used to inform and help predict patient outcomes, as well as serve as a guide for preventive measures, such as surveillance and risk reduction strategies, in individuals with an increased risk of developing cancer. MLH1: Detection of methylation of the MLH1 gene promoter on FFPE, adjunct to MSI, MMR IHC, and for colon or endometrial tumours demonstrating MSI-H and loss of MLH1 protein expression MGMT: Detection of methylation of MGMT gene promoter on FFPE, for prognostic and predictive value for glioblastoma patients.
